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Purpose: The aim of this study was to investigate the association of preoperative C-re-
active protein (CRP) elevation and thrombocytosis with the prognosis of patients with 
non-metastatic renal cell carcinoma (RCC).
Materials and Methods: This was a retrospective review of the medical records of 177 
patients (130 men and 47 women) with non-metastatic RCC who underwent a radical 
nephrectomy between March 2000 and May 2008 and for whom preoperative CRP and 
platelet data were available for analysis. Preoperative CRP elevation and thrombocy-
tosis were compared with clinical and pathological variables.
Results: There were 38 patients with CRP elevation and 11 patients with thrombo-
cytosis. The mean follow-up time was 48.3 months (median, 48.0; range, 13-111 
months). Twenty-three patients (13.0%) developed metastases and six patients died 
during the follow-up period. CRP elevation was significantly correlated with anemia 
(p=0.001), T stage (p=0.004), grade (p=0.025), and metastasis (p＜0.001). Thrombocy-
tosis was significantly correlated with anemia (p=0.003), T stage (p=0.002), and meta-
stasis (p=0.001). The univariate analysis identified anemia, CRP elevation, thrombocy-
tosis, tumor histology subtype, tumor size, T stage, and grade as significant prognostic 
factors associated with recurrence-free survival, whereas the multivariate analyses 
showed that CRP elevation (p=0.033) and tumor size (p=0.007) were independent prog-
nostic factors.
Conclusions: Preoperative CRP elevation and thrombocytosis were associated with a 
poorer prognosis and a higher recurrence rate in patients with non-metastatic RCC. 
Moreover, preoperative CRP elevation appeared to be an independent predictor of tu-
mor recurrence and prognosis. Preoperative thrombocytosis, however, was not an in-
dependent prognostic factor for tumor recurrence and prognosis.
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INTRODUCTION
Renal cell carcinoma (RCC) is the most common primary 
malignant neoplasm of the kidney and accounts for about 
3% of all adult neoplasms [1]. The incidence of RCC has 
been increasing during the past two decades in all age 
groups. The greatest increase has been in patients with lo-
calized tumors as a result of incidental detection, which is 
thought to be the result of more widespread use of abdomi-
nal ultrasound and computed tomography [2]. However, 
about 30% of patients with RCC already have metastatic 
disease at the time of diagnosis, and 10% to 14% of patients 
experience local recurrence or distant metastasis after 
nephrectomy despite a finding of pathologically confined 
disease at the time of nephrectomy [3-5].
　Well-known pathological and clinical variables have Korean J Urol 2011;52:104-109
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TABLE 1.  Clinicopathological data of 177 patients with renal cell 
carcinoma
Characteristics No. of patients (%)
Age (yr)
＜60 113 (63.8)
≥60   64 (36.2)
Gender
Male 130 (73.4)
Female   47 (26.6)
Anemia
No 165 (93.2)
Yes   12 (6.8)
Histology
Conventional 160 (90.4)
Papillary     8 (4.5)
Chromophobe     7 (4.0)
Collecting duct     2 (1.1)
Tumor size (cm)
＜7 137 (77.4)
≥7   40 (22.6)
T stage
T1 129 (72.9)
T2   12 (6.8)
T3   36 (20.3)
T4     0 (0)
Grade
1   35 (19.8)
2   54 (30.5)
3   73 (41.2)
4   15 (8.5)
Metastasis at follow-up
No 154 (87.0)
Yes   23 (13.0)
been identified and sometimes integrated into nomograms 
to better predict disease recurrence, but with only partial 
success. With a better understanding of the biology of RCC, 
laboratory values and molecular markers are increasingly 
being investigated as potential predictive factors for RCC 
[6-8].
　Disease progression appears to depend on a complex in-
teraction between the tumor and host inflammatory res-
ponses. It is estimated that underlying infection and in-
flammatory responses are linked to 15% to 20% of all deaths 
from cancer worldwide [9]. The serum level of C-reactive 
protein (CRP), a nonspecific inflammatory acute-phase 
protein, is frequently increased in patients with metastatic 
RCC and is a predictor of prognosis [10].
　Thrombocytosis is classified according to its etiology as 
primary or secondary. Primary thrombocytosis occurs in 
chronic myeloproliferative and in some myelodysplastic 
disorders [11]. However, secondary thrombocytosis has 
been reported with many malignant diseases; the survival 
of such patients has been reported to be significantly short-
er [12,13]. The prognostic value of the platelet count has 
been studied in patients with localized and metastatic 
RCC; patients with thrombocytosis had a poorer survival 
than did patients with a normal platelet count [14,15].
　The purpose of this study was to investigate the associa-
tion of preoperative CRP elevation and thrombocytosis 
with the prognosis of patients with non-metastatic RCC.
MATERIALS AND METHODS
The medical records of 177 patients with non-metastatic 
RCC who underwent a radical nephrectomy between 
March 2000 and May 2008 and for whom preoperative CRP 
and platelet levels were available for analysis were retro-
spectively reviewed. There were 130 men and 43 women, 
with a mean age of 53.5 years (range, 28-83 years). 
Preoperatively, all patients were evaluated with a physical 
examination, routine hematology and biochemical analy-
sis, and radiology studies, including abdominal computed 
tomography and chest X-ray. The tumors were staged by 
using the 2002 TNM classification of the American Joint 
Committee on Cancer (AJCC) [16] and were graded accord-
ing to Fuhrman's nuclear grading system [17]. All patients 
were evaluated postoperatively every 3 months for the first 
2 years, every 6 months for the next 2 years, and yearly 
thereafter. CRP elevation was defined as a CRP level ≥0.8 
mg/dl, and thrombocytosis was defined as a platelet count 
≥380,000/μl in men and ≥370,000/μl in women according 
to the normal reference range in our hospital. Disease re-
currence was defined as local failure in the tumor bed or 
regional lymph nodes or distant metastasis.
　The chi-square test or Fisher’s exact test was used to ana-
lyze the correlation between preoperative CRP elevation 
or thrombocytosis and the clinical and pathological varia-
bles, including age, gender, anemia, histology subtype, tu-
mor size, T stage, nuclear grade, and metastasis during fol-
low-up. Univariate and multivariate analyses were per-
formed by using the log-rank test or the Cox proportional 
hazards regression model. For all tests, p＜0.05 was con-
sidered to indicate statistically significant differences.
RESULTS
The clinical and pathological characteristics of the 177 pa-
tients with non-metastatic RCC are summarized in Table 
1. The mean tumor size was 5.12 cm (median, 4.50; range, 
1-22 cm). Regional lymph node dissection was performed 
in 24 patients who showed suspicious lymph node meta-
stasis on computed tomography. However, none had a 
pathological diagnosis of lymph node metastasis. There 
were 38 patients (21.5%) with CRP elevations and 11 pa-
tients (6.2%) with thrombocytosis. Among patients with 
CRP elevation, 36 patients (94.7%) showed CRP normal-
ization after surgery. The normalization occurred within 
3 months of the radical nephrectomy. The mean follow-up 
period was 48.3 months (median, 48.0; range, 13-111 
months). Twenty-three patients (13.0%) developed meta-
stases and six patients died during the follow-up period.
　Preoperative CRP elevation was significantly correlated 
with anemia (p=0.001), T stage (p=0.004), grade (p=0.025), Korean J Urol 2011;52:104-109
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TABLE 2. Relationship between preoperative C-reactive protein 
(CRP) level and clinicopathological variables in 177 patients 
with renal cell carcinoma
CRP CRP 
Variables ＜0.8 mg/dl ≥0.8 mg/dl p-value
(n=139) (n=38)
Age (yr) 0.389
   ＜60   91 (80.5) 22 (19.5)
   ≥60   48 (75.0) 16 (25.0)
Gender 0.970
   Male 102 (78.5) 28 (21.5)
   Female   37 (78.7) 10 (21.3)
Anemia 0.001
   No 135 (81.8) 30 (18.2)
   Yes     4 (33.3)   8 (66.7)
Histology 0.209
   Conventional 128 (80.0) 32 (20.0)
   Non-conventional   11 (64.7)   6 (35.3)
Tumor size (cm) 0.053
   ＜7 112 (81.8) 25 (18.2)
   ≥7   27 (67.5) 13 (32.5)
T stage 0.004
   Low (T1＋T2) 117 (83.0) 24 (17.0)
   High (T3＋T4)   22 (61.1) 14 (38.9)
Grade 0.025
   Low (G1＋G2)   76 (85.4) 13 (14.6)
   High (G3＋G4)   63 (71.6) 25 (28.4)
Metastasis at follow-up  ＜0.001
   No 130 (84.4) 24 (15.6)
   Yes     9 (39.1) 14 (60.9)
TABLE 3. Relationship between preoperative platelet count and 
clinicopathological variables in 177 patients with renal cell 
carcinoma
Without With 
Variables thrombocytosis thrombocytosis p-value
(n=166) (n=11)
Age (yr) 0.748
   ＜60 105 (92.9) 　8 (7.1)
   ≥60   61 (95.3) 　3 (4.7)
Gender 0.070
   Male 125 (96.2) 　5 (3.8)
   Female   41 (87.2) 　6 (12.8)
Anemia 0.003
   No 158 (95.8) 　7 (4.2)
   Yes     8 (66.7) 　4 (33.3)
Histology 1.000
   Conventional 150 (93.8)  10 (6.2)
   Non-conventional   16 (94.1) 　1 (5.9)
Tumor size (cm) 0.128
   ＜7 131 (95.6) 　6 (4.4)
   ≥7   35 (87.5) 　5 (12.5)
T stage 0.002
   Low (T1＋T2) 137 (97.2) 　4 (2.8)
   High (T3＋T4)   29 (80.6) 　7 (19.4)
Grade 0.340
   Low (G1＋G2)   85 (95.5) 　4 (4.5)
   High (G3＋G4)   81 (92.0) 　7 (8.0)
Metastasis at follow-up 0.001
   No 149 (96.8) 　5 (3.2)
   Yes   17 (73.9) 　6 (26.1)
and metastasis (p＜0.001), but not with age, gender, tumor 
histology subtype, or tumor size (Table 2). Preoperative 
thrombocytosis was significantly correlated with anemia 
(p=0.003), T stage (p=0.002), and metastasis (p=0.001), but 
not with age, gender, tumor histology subtype, tumor size, 
or grade (Table 3). No significant correlation was found be-
tween preoperative CRP levels and platelet counts when 
analyzed by using Pearson’s correlation coefficient (r= 
0.132, p=0.079).
　Kaplan-Meier recurrence-free survival curves accord-
ing to CRP level showed that the survival rate of patients 
with CRP elevation (CRP≥0.8 mg/dl) was significantly 
lower than that of patients with normal CRP levels (p
＜0.001) (Fig. 1). The univariate analysis identified ane-
mia, CRP elevation, thrombocytosis, tumor histology sub-
type, tumor size, T stage, and grade as significant prog-
nostic factors for recurrence-free survival, whereas the 
multivariate analysis showed that CRP elevation (p= 
0.033) and tumor size (p=0.007) were independent prog-
nostic factors (Table 4).
DISCUSSION
CRP is an acute phase reactant that is produced exclusively 
by hepatocytes in response to cytokines such as interleukin 
(IL)-6, which are known mediators of ongoing inflamma-
tory processes. An elevation of the serum concentration of 
this protein indicates the presence of acute inflammation, 
which is observed 8 to 12 hours after the onset of infection 
[18]. The relationship between cancer and CRP elevation 
is explained by overproduction of IL-6 by tumor cells [19]. 
Hepatic production of CRP is induced by cytokines such as 
IL-1, tumor necrosis factor (TNF), and primarily IL-6, 
which is frequently overproduced by the tumor cells them-
selves [18]. Experimental studies on RCC cell lines and ex-
pression studies of renal surgical specimens have shown 
that at least some renal tumors produce IL-6, which func-
tions as an autocrine growth factor of the RCC [20]. 
Therefore, the presence of a systemic inflammatory re-
sponse might be associated with aggressive RCC behavior.
　The prognostic value of CRP levels has been reported in 
many recent studies of cancers, including those of the 
esophagus, ovaries, and colon [21-23]. However, the mech-
anism by which a systemic inflammatory response affects 
cancer-specific survival in patients with RCC is unclear. 
Hwang et al studied the relationship between CRP and sur-
vival in patients with RCC who underwent a radical neph-
rectomy [24]. They reported a statistically insignificant dif-
ference in the survival rates of patients with and without 
CRP elevation and concluded that CRP was not a sig-
nificant prognostic factor for RCC when compared with tu-
mor stage, grade, tumor size, and cell type. However, Korean J Urol 2011;52:104-109
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FIG. 1. Kaplan-Meier recurrence-free survival curves according 
to C-reactive protein (CRP) level. The survival rate of patients 
with CRP elevation (CRP≥0.8 mg/dl) was significantly lower 
than that of patients with a normal CRP level (p＜0.001).
TABLE 4. Univariate and multivariate analysis of recurrence- 
free survival in 177 patients with renal cell carcinoma
Univariate Multivariate
p-value
Hazards ratio 
(95% CI)
p-value
 Age (＜60 vs. ≥60 yr) 0.262  1.332  0.591
(0.468-3.791)
 Gender (male vs. female) 0.715  1.351  0.543
(0.512-3.561)
 Anemia (no vs. yes) ＜0.001  1.132  0.867
(0.265-4.843)
 CRP (＜0.8 vs.  ＜0.001  3.123  0.033
   ≥0.8 mg/dl) (1.099-8.872)
 Thrombocytosis  ＜0.001  2.845  0.155
   (no vs. yes)   (0.673-12.022)
 Histology (conventional vs.  0.032  2.714  0.079
   non-conventional) (0.889-8.284)
 Tumor size (＜7 vs.  ＜0.001  4.181  0.007
   ≥7 cm) (1.478-11.828)
 T stage (T1＋T2 vs.  ＜0.001  2.574  0.126
   T3＋T4) (0.766-8.647)
 Grade (G1＋G2 vs.  0.009  1.438  0.509
   G3＋G4) (0.489-4.234)
CI: confidence interval, CRP: C-reactive protein
Komai et al demonstrated that the 5-year and 10-year dis-
ease-specific survival rates (75% and 30%, respectively) in 
patients with high CRP levels were significantly worse 
than the rates in patients with normal CRP levels (both 
93%, p＜0.001) and suggested that the preoperative CRP 
level is associated with poor survival in patients with lo-
calized RCC [25]. In addition, they reported that the CRP 
level is a useful preoperative screening tool in patients with 
localized RCC. Blay et al reported that pretreatment IL-6 
and CRP were significantly associated with the effects of 
cytokine therapy and high IL-6 and that the CRP level in-
dicated a poor response to cytokine therapy [26].
　In the present study, preoperative CRP elevation was as-
sociated with a poorer prognosis and a higher recurrence 
rate in patients with non-metastatic RCC. This result con-
firms the importance of the preoperative CRP level as an 
independent prognostic factor for tumor recurrence and is 
consistent with the findings of earlier reports showing that 
a high CRP level is associated with poor survival in lo-
calized RCC [15,25].
　Secondary or reactive thrombocytosis has been asso-
ciated with tumor metastasis and poor survival in cancer 
patients. The pathophysiologic mechanism of reactive 
thrombocytosis may be tumor-associated elevation of cir-
culating platelets by tumor-derived humoral factors such 
as IL-6 and macrophage colony-stimulating factor (M- 
CSF) that may be responsible for the development of can-
cer-related thrombocytosis [27]. IL-6 is a potent stimulator 
of megakaryocytopoiesis, and tumor cells have been shown 
to release IL-6 both in vitro and in vivo [27,28]. These ob-
servations suggest that IL-6 plays a role in the develop-
ment of tumor-associated thrombocytosis. 
　Karakiewicz et al analyzed 1828 patients with RCC by 
univariable, multivariable, and predictive accuracy analy-
ses with regard to RCC-specific mortality [29]. In that 
study, they showed that the addition of thrombocytosis to 
the base model (age, tumor size, TNM stage, ECOG-per-
formance status, Fuhrman grade, and histology subtype) 
increased the predictive accuracy by only 0.3% (from 85.3% 
to 85.6%); these changes in predictive accuracy were not 
statistically significant. Consequently, they concluded 
that patients who presented with thrombocytosis did not 
have poorer prognosis than did their counterparts who did 
not exhibit these apparently unfavorable characteristics, 
as long as the effects of the TNM stage, histology, tumor 
grade, and ECOG-performance status were considered. 
However, many investigators have reported that thrombo-
cytosis is related to a poor prognosis in patients with RCC. 
Göğüş et al reported the significance of thrombocytosis in 
localized RCC [14]. In that report, they showed that pa-
tients with thrombocytosis had a mean survival of 45.2 
months compared with 76.6 months in patients without 
thrombocytosis (p=0.0002) and concluded that preopera-
tive thrombocytosis is associated with a poorer survival 
than is a normal platelet count.
　In the present study, we showed that preoperative 
thrombocytosis was significantly correlated with anemia, 
T stage, and metastasis. In addition, thrombocytosis was 
a significant prognostic factor associated with recurrence- 
free survival in the univariate analysis. Therefore, throm-
bocytosis was associated with a poorer prognosis and a 
higher recurrence rate in patients with non-metastatic 
RCC; these findings are consistent with those of previous 
studies [14,15].
　Ito et al showed that preoperative CRP levels and plate-
let counts had a significant correlation and suggested that 
this was because the reactive thrombocytosis and CRP ele-
vation in RCC were both caused by the production of in-Korean J Urol 2011;52:104-109
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flammatory cytokines such as IL-6 [15]. As in the study by 
Ito et al, we analyzed the relationship between pre-
operative CRP and platelet count. However, we did not find 
a statistically significant association between preopera-
tive CRP and platelet count (r=0.132, p=0.079). Therefore, 
the exact relationship between preoperative CRP and pla-
telet count remains to be determined.
　A limitation of this study is that several variables could 
not be considered in the current analysis. Nonetheless, all 
available variables were included, and our findings in-
dicate that several known prognostic factors were valuable 
as prognostic factors. However, T stage and grade were not 
significant in the multivariate analysis. The reason for this 
result was, to some extent, too many patients in stage T1 
rather than other T stages and a small number of patients 
with grade 4 compared with other grades according to the 
early detection of RCC nowadays.
CONCLUSIONS
Preoperative CRP elevation and thrombocytosis were as-
sociated with a poorer prognosis and a higher recurrence 
rate in patients with non-metastatic RCC. Moreover, pre-
operative CRP elevation was an independent predictor for 
tumor recurrence and prognosis. However, preoperative 
thrombocytosis was not an independent prognostic factor 
for tumor recurrence and prognosis. 
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